Olema Pharmaceuticals, Inc. (OLMA): Cash & Equivalents
$48.30M
As of 2025-12-31
$48.60M
As of 2026-06-30
+26.8%
3-year compound annual growth
-32.3%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $48.30M | -65.4% | 2026-03-16, Balance as of period end |
| 2024-12-31 | $139.48M | +103.5% | 2026-03-16, Balance as of period end |
| 2023-12-31 | $68.54M | +189.2% | 2025-03-18, Balance as of period end |
| 2022-12-31 | $23.70M | +71.6% | 2024-03-11, Balance as of period end |
| 2021-12-31 | $13.81M | -95.9% | 2023-03-09, Balance as of period end |
| 2020-12-31 | $338.55M | n/a | 2022-02-28, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | 2025-12-31 | $48.30M | -65.4% |
| Dianthus Therapeutics, Inc. (DNTH) | 2025-12-31 | $51.09M | +124.1% |
| Syndax Pharmaceuticals Inc (SNDX) | 2025-12-31 | $134.93M | -12.4% |
| Edgewise Therapeutics, Inc. (EWTX) | 2025-12-31 | $61.15M | +46.8% |
| Rigel Pharmaceuticals Inc (RIGL) | 2025-12-31 | $40.58M | -28.5% |
| Rapport Therapeutics, Inc. (RAPP) | 2025-12-31 | $52.65M | -7.3% |
| Ardelyx, Inc. (ARDX) | 2025-12-31 | $68.00M | +4.7% |
| Standard Biotools Inc. (LAB) | 2025-12-31 | $120.86M | -27.5% |
| Geron Corp (GERN) | 2025-12-31 | $77.56M | -1.8% |
Compare OLMA, DNTH, SNDX, EWTX side by side · Screen every company in Pharmaceutical Preparations ↗